DSIP for sleep: evidence regarding insomnia, sleep quality and sleep deprivation

Delta sleep-inducing peptide (DSIP) has shown some sleep-related effects in small, mostly older human studies, but available data do not support its efficacy or approved use in the treatment of insomnia, reduced sleep quality, or the effects of sleep deprivation.

DSIP is often described on the internet as the „sleep peptide”, yet the name itself suggests a level of certainty that the scientific literature does not support. In a few studies conducted mainly from the late 1970s to the early 1990s, changes related to sleep onset latency, sleep efficiency, nocturnal awakenings or deep NREM sleep were observed. On the other hand, other controlled studies showed effects that were minor, statistically uncertain or of limited clinical significance. Animal study results were also inconsistent: depending on the species, route of administration, timing of administration and the studied form of the DSIP molecule, it increased deep slow-wave sleep, caused minimal changes or even reduced sleep.

The practical interpretation of these data should therefore remain cautious. DSIP is an experimental nonapeptide with a not fully elucidated physiological role and mechanism of action, rather than an established sleep medication. It should not be treated as a substitute for melatonin, approved insomnia medications, or cognitive behavioural therapy for insomnia (CBT-I). Designations such as „DSIP 5 mg” merely inform about the declared amount of material in the vial; they do not imply a clinically validated human dose or confirm that the product in question has been tested for the treatment of insomnia.

What is delta sleep-inducing peptide?

Delta sleep-inducing peptide is a nine-amino-acid peptide, also known by the international non-proprietary name emideltide, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was identified during experiments in which venous blood collected from the cerebral vessels of sleeping rabbits appeared to promote sleep-related electroencephalographic activity in other rabbits. In basic animal studies, synthetic DSIP administered directly into the brain increased EEG features associated with sleep spindle and delta activity, which contributed to the hypothesis that DSIP may act as an endogenous sleep-promoting substance [1].

However, this early observation did not confirm the physiological role of DSIP in humans. Later reviews highlighted that researchers had failed to identify a unique gene encoding DSIP, a typical peptide precursor or a specific DSIP receptor. Measurements referred to as „DSIP-like immunoreactivity” may detect DSIP that is part of larger molecules or chemically similar material, rather than freely circulating, unaltered DSIP. Its natural concentrations, secretion pattern, metabolism and physiological function therefore remain uncertain [2,3]. Describing DSIP as a sleep-inducing peptide reflects the circumstances of its discovery, but does not mean that modern clinical research has confirmed it as a natural human sleep hormone.

Sleep itself encompasses several distinct physiological states. Polysomnography combines an EEG recording with the monitoring of eye movements and muscle tone to distinguish NREM sleep from REM sleep. Contemporary classification divides NREM sleep into stages N1, N2 and N3, with N3 corresponding to slow-wave, or deep, sleep. Older studies on DSIP used terms such as stage 1, stage 2, stages 3 and 4, „deep slow-wave sleep” or „paradoxical sleep”; paradoxical sleep essentially corresponds to the REM phase, whereas the former stages 3 and 4 are now combined as N3. Terminological differences matter because an increase in delta wave activity on the EEG does not necessarily imply a longer total sleep time, faster sleep onset, or better functioning the following day.

Does DSIP help you fall asleep and sleep?

DSIP may affect certain sleep parameters under experimental conditions, but data from human studies are too limited, old and inconsistent to state that the peptide reliably improves sleep.

Some of the most favourable results came from small studies by Schneider-Helmert and colleagues. In one double-blind crossover study involving just six healthy volunteers, slow intravenous administration of DSIP in the morning was associated with greater sleep pressure and longer sleep during a daytime nap opportunity; a subsequent night-time recording showed shorter sleep latency, less stage 1 sleep and greater sleep efficiency [4]. In another experiment involving six middle-aged individuals with chronic insomnia, DSIP was associated with longer, less fragmented sleep and a slight increase in REM sleep, with the most noticeable sleep-promoting effect appearing only in the second hour [5]. These observations suggest a possible delayed regulatory action rather than the rapid and predictable sedation typical of classic sleeping pills.

Several subsequent publications by the same or a related research group described improvements following repeated intravenous administration of DSIP in small groups of people with chronic insomnia [6–9]. However, these publications should not be interpreted as a series of large, independent replication studies. They originated from a limited research network, involved small sample sizes, and some summarised overlapping experiments or observations without a control group. One open-label study involved seven patients, six of whom were reported to have experienced sustained improvement; however, in the absence of a blinded placebo group, it was not possible to distinguish the effect of DSIP from participants’ expectations, regression to the mean, changes in sleep schedules or the naturally variable course of insomnia [7].

Independent controlled trials yielded far less convincing results. In a double-blind crossover trial, Monti and colleagues observed a numerical reduction in the number of awakenings, the time to onset of NREM sleep, total wakefulness time and wakefulness time after falling asleep; however, these differences were not statistically significant compared with baseline or placebo. Total sleep time and NREM sleep time increased mainly due to a prolongation of stage 2, rather than deep slow-wave sleep, whilst stages 3 and 4 and REM sleep remained essentially unchanged. The authors concluded that the observed changes were of little clinical significance [10]. In a subsequent double-blind, parallel-group trial involving 16 people with chronic insomnia, DSIP appeared to improve sleep efficiency and reduce the time taken to fall asleep; however, the effect was weak and was partly due to a random change in the placebo group. Participants did not report any improvement in subjective sleep quality, and the authors concluded that a significant therapeutic benefit was unlikely [11].

Taken together, these findings represent a signal of interest from both a historical and mechanistic perspective, but do not provide reliable evidence of effective treatment. No large, contemporary, multicentre, randomised trial has been conducted to demonstrate a significant improvement in the severity of insomnia, daytime functioning, recurrence rates or long-term quality of life.

Does DSIP cause drowsiness or make it easier to fall asleep?

There is no evidence that DSIP causes immediate drowsiness, and small-scale studies involving humans suggest that any effects relating to sleep may be delayed, irregular and different from those of typical sedatives.

In a crossover study involving six volunteers, the researchers reported increased sleep pressure but not the typical pattern of sedative effects [4]. In a study involving six people with insomnia, even mild agitation was observed in the first hour after administration, whilst more beneficial changes mainly appeared in the second hour [5]. A subsequent summary by the same research group suggested that the onset of action occurred after approximately one hour and that the effect persisted beyond the administration period itself; however, this interpretation was based on several very small, related studies rather than on a conclusive pharmacodynamic study [6].

Sleep onset time is just one element of sleep. A person may fall asleep more quickly and at the same time spend more time awake later in the night, fail to obtain any extra deep sleep or feel any better the next day. On the other hand, a given intervention may alter EEG activity or the proportions of individual sleep phases without causing noticeable drowsiness. Available DSIP research has not shown a consistent link between objective polysomnography results and a subjective sense of being rested, daytime alertness or improved functioning. For this reason, claims that DSIP simply sends one to sleep go beyond what has actually been demonstrated in studies.

Nor is there an evidence-based method for converting a product label, such as „DSIP (delta sleep-inducing peptide) – 5 mg”, into the expected time taken to fall asleep. Historical human studies have typically used controlled intravenous administration, with exposure determined in relation to body weight or in molar units, rather than on the basis of the commercial strength of the vial. Purity, molecular identity, formulation, route of administration and pharmacokinetics may all influence exposure. The quantity stated on the vial does not constitute a clinical treatment protocol, and the available studies do not support the use of DSIP on its own to improve sleep.

DSIP and the architecture of sleep

In some experiments DSIP increased activity characteristic of deep slow-wave sleep, but it has not been shown to consistently improve overall sleep architecture in humans.

Sleep architecture refers to the pattern and proportions of NREM and REM phases throughout the night, including the cyclical transitions between lighter sleep (N1/N2), deep sleep (N3) and the REM phase. A clinically useful intervention should, first and foremost, address a specific problem, such as taking a long time to fall asleep or excessive wakefulness after falling asleep, without causing adverse effects the following day and without disrupting the restorative phases of sleep. Greater delta wave activity does not, therefore, automatically mean better sleep.

Studies involving humans do not show a consistent pattern of changes in the individual sleep stages. An early experiment involving six patients with insomnia showed fewer sleep interruptions and a slight increase in REM sleep, although the sample size was very small [5]. Monti and colleagues reported an increase in NREM sleep, mainly due to a prolongation of stage 2, whilst slow-wave stages 3 and 4 and REM sleep remained virtually unchanged [10]. A double-blind study involving 16 participants showed only minor objective changes without a corresponding improvement in the perceived quality of sleep [11]. The inconsistency of these results makes it impossible to reliably conclude that native DSIP increases N3, REM or a specific, beneficial profile of restorative sleep in humans.

Animal studies additionally show why straightforward conclusions are unjustified. In one study involving ten cats, administering DSIP into the brain increased total and deep slow-wave sleep and shortened sleep onset latency [12]. Subcutaneous administration in eight cats increased deep slow-wave sleep and EEG delta activity, but did not significantly affect total wakefulness time, total slow-wave sleep time, sleep onset latency or the length of the REM phase [13]. Conversely, in another study, intraperitoneal administration of DSIP restricted sleep, particularly light slow-wave sleep and REM, while prolonging the latency to REM [14]. These results stem from different experimental conditions and demonstrate biological variability rather than a confirmed sleep effect in humans.

Research into phosphorylated DSIP further complicates the picture. The phosphorylated analogue increased slow-wave and paradoxical/REM sleep in rats, whilst another study in rats showed an increase in both types of sleep during prolonged cerebral infusion [15,16]. However, phospho-DSIP is a chemically distinct molecule from native DSIP. The findings regarding this analogue cannot be taken as evidence that ordinary DSIP produces the same effect in humans, at the same time and with the same intensity.

Table of evidence: what DSIP sleep research really shows

DSIP for insomnia: what did clinical trials show?

Clinical studies on DSIP in insomnia have been limited and have yielded conflicting results, with better-controlled trials showing no clear or clinically significant benefit.

Chronic insomnia is more than just a single badly slept night. It is characterised by persistent difficulties with falling asleep, staying asleep, or obtaining restorative sleep, which are accompanied by daytime consequences. Modern clinical trials typically use clearly defined diagnostic criteria, appropriate randomisation, pre-defined endpoints, validated insomnia questionnaires, polysomnography or actigraphy where justified, systematic monitoring of adverse events, and adequately large samples allowing a true treatment effect to be distinguished from the natural night-to-night variability of sleep. Most DSIP studies were conducted before many of these standards became routine.

The more favourable studies included acute experiments involving six patients, small repeat-dose series, a placebo-controlled study with 14 subjects, and an 18-person study describing the normalisation of some sleep parameters following a short cycle [5–9]. These publications are relevant because they represent real human studies rather than solely extrapolation from animal experiments. However, they still do not establish whether DSIP produces reproducible, clinically meaningful improvement. Small trials increase the risk of accidental findings, selective reporting becomes more problematic when analysing multiple sleep phases and time intervals, and the short observation period makes it difficult to assess the durability of the effect and adverse reactions.

Particularly important are negative or ambiguous controlled studies. Monti and co-workers failed to demonstrate a significant, placebo-adjusted improvement in primary sleep continuity parameters or an increase in slow-wave or REM sleep [10]. Bes and co-workers also failed to show an improvement in subjective sleep quality and concluded that a significant therapeutic benefit was unlikely [11]. Although both studies were small by contemporary standards, together they weaken the claim that clinical trials consistently support the efficacy of DSIP in the treatment of insomnia.

Nor is there an extensive Phase 2 or 3 research programme determining the dose-response relationship, optimal formulation, risk of interactions, withdrawal effects or comparative efficacy. Describing historical publications as „DSIP clinical trials” is correct in a broad sense, but should not suggest the scale or regulatory rigour characteristic of modern insomnia drug development. No published data support DSIP as a replacement for CBT-I or an approved medication tailored to an individual patient's diagnosis and risk profile.

DSIP and sleep quality

DSIP has not shown a consistent improvement in sleep quality, particularly when quality was assessed by the individual themselves rather than solely on the basis of EEG or other laboratory measurements.

Objective and subjective sleep parameters are related, but they are not the same thing. Polysomnography can measure sleep onset latency, total sleep time, wakefulness after sleep onset, sleep efficiency, stage distribution, awakenings and EEG activity. Subjective results, on the other hand, assess whether sleep felt restorative, whether awakenings were troublesome and whether daytime energy, concentration, mood or functioning have improved. Treatment may alter a laboratory parameter without simultaneously providing a noticeable benefit to the patient.

Such discrepancies are evident in the literature concerning DSIP. Some early studies described objectively longer or less fragmented sleep [4,5], whereas a controlled study involving 16 individuals showed no improvement in subjective sleep quality despite ostensibly favourable changes in sleep efficiency and sleep latency [11]. The literature also lacks contemporary, validated endpoints, such as a change in the Insomnia Severity Index, patient global impression of change, sustained improvement in daytime functioning, or clinically defined remission.

Claims that DSIP provides „restorative” or „higher quality” sleep should therefore be treated as hypotheses rather than proven benefits. Greater delta activity in an animal's EEG does not mean that a human will wake up feeling more refreshed. Similarly, a minor change observed during a single laboratory night does not prove better sleep in home conditions, where quality is influenced by, among other things, stress, light, working hours, stimulants, breathing disorders, restless legs syndrome, pain and psychological problems.

DSIP in sleep deprivation research

Sleep deprivation research has not shown DSIP to reliably replace lost sleep, prevent functional decline, or accelerate recovery in humans.

In one experiment involving cats, DSIP was evaluated after 72 hours of selective paradoxical/REM sleep deprivation. Administration into the brain did not significantly alter total slow-wave sleep time, REM sleep, total sleep time, or sleep onset latency. However, it decreased wakefulness and light slow-wave sleep while increasing the proportion of the deeper stage of slow-wave sleep [17]. This result corresponds more to a redistribution of restorative sleep phases than to an actual replenishment of lost REM sleep. Since the study was performed on animals and involved direct administration into the brain, it cannot constitute proof of efficacy in human sleep deprivation.

In a small observational study involving seven healthy men, plasma DSIP-like immunoreactivity was measured during normal nocturnal sleep, partial nocturnal sleep deprivation, and morning recovery sleep. The measured immunoreactivity decreased during the transition from wakefulness to sleep at various times of the day and was not associated with a specific sleep stage [18]. This is scientifically interesting because it does not fit the simple assumption that circulating DSIP concentrations increase to induce delta sleep. However, the assay measured immunoreactive material rather than necessarily intact biologically active DSIP, and the study did not involve the administration of DSIP or the evaluation of its effect on recovery following sleep deprivation.

There are no reliable human studies showing that DSIP prevents the cognitive, emotional, metabolic, immunological, or safety-related consequences of insufficient sleep. Therefore, it should not be presented as a substitute for an adequate amount of sleep, a countermeasure to shift work fatigue, or a way to „make up” for sleep deprivation. Such uses remain unproven.

Can DSIP cause sleep worsening, lack of sleep, or insomnia?

Theoretically, DSIP may worsen sleep in some situations, but the available studies are definitely too small to estimate the incidence of paradoxical or adverse sleep-related reactions.

Several observations argue against the assumption that DSIP always promotes sleep. In a study involving six individuals with insomnia, a mild arousal was observed in the first hour after administration prior to a subsequent improvement in sleep parameters [5]. In cats, intraperitoneal administration of DSIP reduced light slow-wave sleep and REM sleep, and prolonged the latency to REM onset [14]. In an anaesthesiological study involving 24 women, DSIP altered EEG indices related to depth of anaesthesia and autonomic parameters, with some observations interpreted as a possible lightening rather than a deepening of anaesthesia [19]. These results originate from very different situations and do not allow for the prediction of individual response, but they demonstrate that DSIP does not act as a simple biological sleep switch.

Available literature does not allow the frequency of insomnia, intense dreams, nightmares, daytime sleepiness, rebound increased alertness or REM sleep changes to be determined. The studies were too small and mostly too old to create a contemporary database of adverse reactions. An additional source of uncertainty is the quality of unapproved products sold as research peptides: the label alone does not confirm identity, purity, sterility, concentration or storage stability.

Persistent insomnia, increased daytime sleepiness, loud snoring or episodes of choking, unusual movements during sleep, or sleep deprivation combined with significant mood changes require clinical evaluation. These symptoms may occur in sleep apnoea, circadian rhythm disorders, restless legs syndrome, medication side effects, substance use, depression, anxiety, mania, pain, and other conditions that a peptide experiment cannot diagnose.

DSIP and melatonin

Melatonin has a specific circadian mechanism and a significantly larger base of human studies, whereas for DSIP no specific receptor has been confirmed and there is only a small number of inconsistent studies concerning insomnia.

Melatonin is a hormone produced mainly at night under the control of the circadian timing system. It acts via identified MT1 and MT2 receptors and constitutes a biological signal of darkness that can shift or enhance the timing of sleep. Its efficacy strongly depends on the time of administration, population, formulation and specific sleep problem; it is not a universal sedative. A meta-analysis of 19 randomised placebo-controlled trials involving 1,683 participants showed a statistically significant, but on average modest, improvement in sleep onset latency, total sleep time and sleep quality [20]. Although this evidence base also has limitations, it is considerably larger and more reproducible than the literature concerning DSIP.

In the case of DSIP, however, neither a specific receptor nor an accepted role in the human circadian system has been confirmed [2,3]. Human studies have used experimental intravenous administration and have not shown consistent improvements in sleep or perceived sleep quality [4–11]. Comparing the two compounds solely by their names – „sleep hormone” and „delta sleep-inducing peptide” – therefore overlooks a fundamental difference in the level of evidence.

It should not be assumed that any of these compounds are suitable for every type of sleep problem. Circadian rhythm disorders differ from psychophysiological insomnia, sleep apnoea, medication-induced insomnia or simply insufficient time allocated for sleep. Regulations concerning melatonin and product quality also vary between countries. A lack of efficacy of melatonin does not provide a basis for using unapproved DSIP, and the literature does not establish a validated dose conversion, method of combination, or a direct comparison strategy for the two compounds. Furthermore, no clinical study of DSIP versus melatonin has been conducted that would demonstrate the superiority of one over the other.

DSIP compared to other sleep peptides and sleeping aids

DSIP remains an experimental peptide, whereas established interventions used for insomnia typically have specific therapeutic targets, larger controlled research programmes and better-described safety profiles.

The term „sleep peptide” can refer to biologically very different molecules. Orexin, also called hypocretin, is an endogenous wake-promoting neuropeptide system. Approved orexin receptor antagonists are small molecules that block orexin signalling; they are neither DSIP nor peptide supplements. Other experimental DSIP analogues may also behave differently from the native molecule. For example, a 2024 mouse study tested a modified DSIP fusion construct designed to improve brain delivery in a chemically induced insomnia model. This fusion peptide is not equivalent to native DSIP, and behavioural or neurotransmitter outcomes in mice do not constitute evidence of efficacy in human insomnia [21].

GABAergic sleep aids — including benzodiazepines and the so-called Z-drugs — enhance signalling at specific GABA-A receptor complexes and can facilitate sleep, though depending on the specific drug and patient they are associated with recognised risks such as next-day impairment, falls, tolerance, dependence, and complex sleep behaviours. In an ex vivo experiment on rat neurones, DSIP enhanced GABA-activated currents and affected NMDA/glutamate signalling [22]. However, this mechanistic observation does not make DSIP equivalent to a GABAergic sleep aid, as the study was not conducted in humans and did not establish a therapeutic receptor, clinically relevant exposure, or margin of safety.

CBT-I is not a medicine, but it is important in this comparison because it affects behaviours and cognitive processes that maintain chronic insomnia. It typically includes stimulus control, structured sleep scheduling, cognitive techniques and the modification of behaviours that hinder sleep. Comparing DSIP solely with pharmacological substances may wrongly suggest that chronic insomnia always requires a biological „sleep-inducing” substance.

This comparison does not point to a single universal „winner”. Appropriate management depends on the diagnosis, age, state of health, other medications, pregnancy, the risk of breathing disorders, work schedule, and the balance between nighttime benefit and daytime impairment. However, it shows why DSIP cannot currently be placed on the same level of evidence as established treatments for insomnia.

Limitations of sleep evidence

The literature regarding DSIP and sleep is limited by very small study groups, older research methods, inconsistent results, uncertainty regarding the measurement of the molecule itself, and a lack of contemporary supporting research.

Most human studies included only six to eighteen participants. Such small samples are susceptible to baseline chance differences, seemingly large treatment effects and selective reporting when multiple EEG variables and sleep phases are analysed. Furthermore, several favourable publications came from affiliated researchers and may have presented related or partially overlapping designs rather than fully independent replications. Some studies were open-label or lacked an appropriate placebo group, meaning participant expectations and the natural variability of insomnia represent particularly important confounding factors.

The routes of administration and formulations used in historical studies also limit their usefulness in real-world conditions. In human experiments, DSIP was typically administered slowly intravenously under the supervision of researchers. These studies do not support oral, subcutaneous, intranasal, or other modern commercial preparations, nor do they demonstrate that the amount stated on the retail vial label is safe or effective. Pharmacokinetic data are insufficient to assume comparable brain exposure across different routes of administration.

The biological target of the action itself also remains unexplained. No specific DSIP receptor has been identified, and immunological tests may detect DSIP-like material rather than the intact peptide [2,3,18]. Furthermore, the results of animal studies vary depending on the species, timing of administration, route of administration and molecular form. Native DSIP, phosphorylated DSIP, truncated analogues, KND-related peptides and modified fusion constructs designed for delivery to the brain should therefore be treated as distinct experimental interventions.

Finally, the available data lack many elements expected in modern insomnia therapy development: adequately sized randomised trials, prospectively registered protocols, reproducible dose-response relationships, validated patient-reported symptom severity indices, systematic adverse event assessment, daytime functioning outcomes, comparisons with established treatments, and longer-term follow-up. The absence of evidence does not mean that DSIP has no biological activity, but it constitutes a strong argument against presenting its potential sleep benefits as confirmed clinical effects.

FAQ: DSIP for sleep

Is DSIP a sleeping tablet?

No. Delta sleep-inducing peptide is an experimental nonapeptide, not an approved sleeping pill. Small historical studies tested controlled intravenous administration with inconsistent results. DSIP has no confirmed receptor, established clinical dosage standard for insomnia, or modern efficacy and safety research programme comparable to an approved sleeping pill.

Does DSIP increase deep sleep?

Some animal studies have shown an increase in deep slow-wave sleep or EEG delta activity, but the effect was inconsistent depending on the route of administration and the experiment. Studies in humans with insomnia have not shown a reliable increase in slow-wave sleep; in one controlled study, the increase in NREM sleep resulted mainly from the prolongation of stage 2, while stages 3 and 4 remained unchanged [10]. Therefore, it is not correct to claim that DSIP reliably increases the N3 stage in humans.

Does DSIP increase REM sleep?

Results for native DSIP are mixed. One very small human study showed a slight increase in REM sleep, whereas a controlled study in insomnia showed no significant change in REM [5,10]. Some studies of phosphorylated DSIP in rats showed an increase in paradoxical/REM sleep, whilst another study of native DSIP in cats showed a decrease [14–16]. Differences in molecules, species and routes of administration make it impossible to predict the REM effect in humans.

How quickly does DSIP affect sleep?

There is no clinically established onset time. Early human studies described delayed effects, sometimes preceded by a period of mild stimulation, but these observations come from very small studies involving intravenous administration [4–6]. They cannot be reliably applied to commercial products, other routes of administration, or retail vial strengths.

Is DSIP a proven treatment for chronic insomnia?

No. A few small studies have shown beneficial changes in sleep parameters, but other double-blind studies have shown little clinical significance or no improvement in subjective sleep quality [10,11]. No large, recent studies have been conducted to confirm a sustained improvement in the severity of insomnia or daytime functioning.

Can DSIP replace sleep following sleep deprivation?

There is no evidence that DSIP can replace lost sleep. In an experiment on cats following sleep deprivation, a redistribution towards deeper slow-wave sleep was observed, without an increase in total sleep time or the restoration of lost REM sleep [17]. A small study on sleep deprivation in humans was observational in nature and did not test DSIP treatment [18]. DSIP should not be presented as a safeguard against the health or safety consequences of insufficient sleep.

Is DSIP better than melatonin?

No direct human trial has been conducted to demonstrate the superiority of DSIP over melatonin. Melatonin acts via identified receptors and has a much larger body of randomised trials, although its average benefits are generally modest and depend on the indication and timing of administration [20]. The mechanism and clinical utility of DSIP remain uncertain.

What does „DSIP 5 mg” mean?

Usually, this means that the seller declares the presence of 5 milligrams of material in the vial. This does not mean that 5 mg is a clinically tested dose, that the product's contents have been independently verified, or that regulatory authorities have approved it for use for sleep. The FDA substance database recognises emideltide/DSIP as a chemical identity, but notes that the assignment of a substance identifier does not imply regulatory evaluation or approval [23].

Is DSIP approved by the FDA or EMA for the treatment of insomnia?

No. DSIP, or emideltide, is not an FDA- or EMA-approved treatment for insomnia. The presence of a substance in a regulatory database is not equivalent to a marketing authorisation. Because regulatory status can change, current information should be checked in official FDA and EMA drug databases rather than in sellers' descriptions.

What should you do if you’re having persistent sleep problems?

Persistent insomnia should be assessed in the context of its cause, rather than treated as a presumed „peptide deficiency”. A licensed healthcare professional can evaluate sleep duration, circadian rhythm, medications and substances used, mental and physical health, sleep apnoea, restless legs syndrome and other potential causes, and then discuss evidence-based treatment methods. Urgent evaluation is particularly important when sleep deprivation is accompanied by dangerous daytime sleepiness, pauses in breathing, mania, suicidal ideation or other acute symptoms.

Disclaimer

This content is for educational and scientific-informational purposes only and should not be interpreted as medical advice, a diagnosis, a treatment recommendation, dosage information or a recommendation to use DSIP. This article should not be used for the self-treatment of sleep disorders or for making decisions regarding the purchase, preparation, reconstitution or self-administration of an unapproved peptide. Delta sleep-inducing peptide (DSIP/emideltide) is an experimental peptide and has not been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of insomnia, sleep deprivation, improving sleep quality, or any other sleep-related indication discussed in this article. The available data from human studies are limited, largely date back several decades and are inconsistent, whilst a significant proportion of the additional literature comprises animal studies, ex vivo experiments or mechanistic observations.

References

1. Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America, 74(3), 1282–1286. https://doi.org/10.1073/pnas.74.3.1282
2. Graf, M. V., & Kastin, A. J. (1986). Delta-sleep-inducing peptide (DSIP): An update. Peptides, 7(6), 1165–1187. https://doi.org/10.1016/0196-9781(86)90148-8
3. Kovalzon, V. M., & Strekalova, T. V. (2006). Delta sleep-inducing peptide (DSIP): A still unresolved riddle. Journal of Neurochemistry, 97(2), 303–309. https://doi.org/10.1111/j.1471-4159.2006.03693.x
4. Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behaviour. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 19(8), 341–345. https://pubmed.ncbi.nlm.nih.gov/6895513/
5. Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
6. Schneider-Helmert, D., & Schoenenberger, G. A. (1983). Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology, 9(4), 197–206. https://doi.org/10.1159/000117964
7. Kaeser, H. E. (1984). A clinical trial with DSIP. European Neurology, 23(5), 386–388. https://doi.org/10.1159/000115717
8. Schneider-Helmert, D. (1986). Efficacy of delta-sleep-inducing peptide to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology, 25(6), 448–453. https://doi.org/10.1159/000116050
9. Schneider-Helmert, D. (1987). Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology, 27(2), 120–129. https://doi.org/10.1159/000116143
10. Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of the efficacy of delta sleep-inducing peptide in the treatment of insomnia. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
11. Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919
12. Susić, V., Masirević, G., & Totić, S. (1987). Effects of delta sleep-inducing peptide on wakefulness and sleep patterns in the cat. Brain Research, 414(2), 262–270. https://doi.org/10.1016/0006-8993(87)90006-0
13. Susić, V. (1987). Effects of subcutaneous administration of delta sleep-inducing peptide on the sleep-waking cycle in the cat. Physiology & Behavior, 40(5), 569–572. https://doi.org/10.1016/0031-9384(87)90098-9
14. Sommerfelt, L. (1985). Reduced sleep in cats after intraperitoneal injection of delta sleep-inducing peptide. Neuroscience Letters, 58(1), 73-77. https://doi.org/10.1016/0304-3940(85)90331-3
15. Nakagaki, K., Ebihara, S., Usui, S., Honda, Y., & Takahashi, Y. (1988). Sleep-promoting effect of delta sleep-inducing peptide (DSIP) following the intracerebroventricular injection of its phosphorylated analogue in the rat. Neuroscience Letters, 91(2), 160–164. https://doi.org/10.1016/0304-3940(88)90761-6
16. Kimura, M., & Inoué, S. (1989). The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats. Psychopharmacology, 97(1), 35–39. https://doi.org/10.1007/BF00443409
17. Susić, V., & Masirević, G. (1985). Effects of delta sleep-inducing peptide on the sleep cycle of cats deprived of paradoxical sleep. Archives Internationales de Physiologie et de Biochimie, 93(4), 271–277. https://doi.org/10.3109/13813458509079606
18. Seifritz, E., Müller, M. J., Schönenberger, G. A., Trachsel, L., Hemmeter, U., Hatzinger, M., Ernst, A., Moore, P., & Holsboer-Trachsler, E. (1995). Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides, 16(8), 1475–1481. https://doi.org/10.1016/0196-9781(95)02027-6
19. Pomfrett, C. J. D., Dolling, S., Anders, N. R. K., Glover, D. G., Bryan, A., & Pollard, B. J. (2009). Delta sleep-inducing peptide alters bispectral index, electroencephalographic power spectrum, and heart rate variability during isoflurane anaesthesia. European Journal of Anaesthesiology, 26(2), 128–134. https://doi.org/10.1097/EJA.0b013e32831c8644
20. Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: Melatonin for the treatment of primary sleep disorders. PLOS ONE, 8(5), e63773. https://doi.org/10.1371/journal.pone.0063773
21. Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA insomnia mouse models. Frontiers in Pharmacology, 15, 1439536. https://doi.org/10.3389/fphar.2024.1439536
22. Grigor’ev, V. V., Ivanova, T. A., Kustova, E. A., Petrova, L. N., Serkova, T. P., & Bachurin, S. O. (2006). Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bulletin of Experimental Biology and Medicine, 142(2), 186–188. https://doi.org/10.1007/s10517-006-0323-9
23. U.S. Food and Drug Administration. (n.d.). Emideltide: UNII YN28Z5YZ73. Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/yn28z5yz73